2-Methoxy-6-methyl-terephthalsaeure | 883-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Methoxy-6-methyl-terephthalsaeure
• 英文别名: 2-methoxy-6-methyl-terephthalic acid；2-Methoxy-6-methylterephthalic acid
• CAS: 883-72-7
• 化学式: C₁₀H₁₀O₅
• 分子量: 210.186
• InChiKey: YUVLWPCKAIKUAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-Methoxy-6-methyl-terephthalsaeure 在 氢碘酸 作用下， 生成 2-hydroxy-6-methyl-terephthalic acid
  参考文献：
  名称：

  Comparison of 0.1% dexamethasone phosphate eye gel (Dexagel) and 1% prednisolone acetate eye suspension in the treatment of post-operative inflammation after cataract surgery

  摘要：

  A prospective, multi-centre, clinical parallel group study was conducted to assess the efficacy and safety of a new 0.1% dexamethasone phosphate eye gel (Group 1, n = 117) compared to 1% prednisolone acetate eye suspension (Group 21, n = 119) in a total of 236 patients (safety population), aged 39-92 years, following cataract surgery. Both drugs were given four times a day for 14 days starting 24 +/- 4 h after surgery. Criteria for evaluation were the reduction in anterior chamber flare and inflammation severity score (primary efficacy criteria) as well as different secondary efficacy and safety evaluation criteria. Laser photometry (LFM-500, Kowa), slit lamp assessment and the examination of other objective and subjective symptoms of ocular discomfort were performed between the last preoperative and 14th post-operative day. There were no statistically significant differences between the treatment groups concerning primary and secondary efficacy criteria. The mean reduction in anterior chamber flare from day I to day 14 post-operatively was 8.34 +/- 20.80 photons/ms with 0.1% dexamethasone eye gel and 5.72 +/- 16.70 photons/ms with 1% prednisolone eye suspension. The mean reduction of inflammation severity score was 1.8 +/- 1.3 points in Group 1 and 2.0 +/- 1.1 points in Group 2. Intra-ocular pressure did not increase after treatment with 0.1% dexamethasone phosphate eye gel. Conclusion: the results of the study underline the protective effect of topically applied 0.1% dexamethasone phosphate eye gel on the blood-aqueous barrier. This drug is an effective and safe steroidal antiinflammatory agent for topical use following cataract surgery and intraocular lens implantation.

  DOI：

  10.1007/s004170100346
• 作为产物：
  描述：

  3-methoxy-4,5-dimethylbenzoic acid 在 potassium permanganate 、 sodium carbonate 作用下， 生成 2-Methoxy-6-methyl-terephthalsaeure
  参考文献：
  名称：

  Comparison of 0.1% dexamethasone phosphate eye gel (Dexagel) and 1% prednisolone acetate eye suspension in the treatment of post-operative inflammation after cataract surgery

  摘要：

  A prospective, multi-centre, clinical parallel group study was conducted to assess the efficacy and safety of a new 0.1% dexamethasone phosphate eye gel (Group 1, n = 117) compared to 1% prednisolone acetate eye suspension (Group 21, n = 119) in a total of 236 patients (safety population), aged 39-92 years, following cataract surgery. Both drugs were given four times a day for 14 days starting 24 +/- 4 h after surgery. Criteria for evaluation were the reduction in anterior chamber flare and inflammation severity score (primary efficacy criteria) as well as different secondary efficacy and safety evaluation criteria. Laser photometry (LFM-500, Kowa), slit lamp assessment and the examination of other objective and subjective symptoms of ocular discomfort were performed between the last preoperative and 14th post-operative day. There were no statistically significant differences between the treatment groups concerning primary and secondary efficacy criteria. The mean reduction in anterior chamber flare from day I to day 14 post-operatively was 8.34 +/- 20.80 photons/ms with 0.1% dexamethasone eye gel and 5.72 +/- 16.70 photons/ms with 1% prednisolone eye suspension. The mean reduction of inflammation severity score was 1.8 +/- 1.3 points in Group 1 and 2.0 +/- 1.1 points in Group 2. Intra-ocular pressure did not increase after treatment with 0.1% dexamethasone phosphate eye gel. Conclusion: the results of the study underline the protective effect of topically applied 0.1% dexamethasone phosphate eye gel on the blood-aqueous barrier. This drug is an effective and safe steroidal antiinflammatory agent for topical use following cataract surgery and intraocular lens implantation.

  DOI：

  10.1007/s004170100346

文献信息

• US4172949A
  申请人：——

  公开号：US4172949A

  公开（公告）日：1979-10-30
• Comparison of 0.1% dexamethasone phosphate eye gel (Dexagel) and 1% prednisolone acetate eye suspension in the treatment of post-operative inflammation after cataract surgery
  作者：Hans Struck、Annett Bariszlovich

  DOI：10.1007/s004170100346

  日期：2001.10

  A prospective, multi-centre, clinical parallel group study was conducted to assess the efficacy and safety of a new 0.1% dexamethasone phosphate eye gel (Group 1, n = 117) compared to 1% prednisolone acetate eye suspension (Group 21, n = 119) in a total of 236 patients (safety population), aged 39-92 years, following cataract surgery. Both drugs were given four times a day for 14 days starting 24 +/- 4 h after surgery. Criteria for evaluation were the reduction in anterior chamber flare and inflammation severity score (primary efficacy criteria) as well as different secondary efficacy and safety evaluation criteria. Laser photometry (LFM-500, Kowa), slit lamp assessment and the examination of other objective and subjective symptoms of ocular discomfort were performed between the last preoperative and 14th post-operative day. There were no statistically significant differences between the treatment groups concerning primary and secondary efficacy criteria. The mean reduction in anterior chamber flare from day I to day 14 post-operatively was 8.34 +/- 20.80 photons/ms with 0.1% dexamethasone eye gel and 5.72 +/- 16.70 photons/ms with 1% prednisolone eye suspension. The mean reduction of inflammation severity score was 1.8 +/- 1.3 points in Group 1 and 2.0 +/- 1.1 points in Group 2. Intra-ocular pressure did not increase after treatment with 0.1% dexamethasone phosphate eye gel. Conclusion: the results of the study underline the protective effect of topically applied 0.1% dexamethasone phosphate eye gel on the blood-aqueous barrier. This drug is an effective and safe steroidal antiinflammatory agent for topical use following cataract surgery and intraocular lens implantation.